By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


Start Up


Dyax  Antibody phage display

Company News
BioSurplus To Auction Lab Assets From Merrimack (MACK) In Cambridge, Mass. 4/26/2017 9:55:33 AM
Merrimack (MACK) Appoints Daryl Drummond, Ph.D. As Head Of Research 4/17/2017 6:56:49 AM
Merrimack (MACK) Declares $140M Special Dividend In Connection With Recently Completed Asset Sale 4/6/2017 8:30:32 AM
Merrimack (MACK) Launches As New, Refocused Research & Clinical Development Company With Resources To Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 And MM-310 4/3/2017 12:20:22 PM
Ipsen (IPN.PA) Completes Acquisition Of ONIVYDE (Irinotecan Liposome Injection) And Additional Oncology Assets From Merrimack (MACK) 4/3/2017 11:27:41 AM
Merrimack (MACK) Stockholders Approve Sale Of ONIVYDE And Generic Version Of DOXIL To Ipsen (IPN.PA) For Up To $1.025 Billion 3/31/2017 7:30:21 AM
Merrimack (MACK) Initiates Phase I Study Of MM-310 In Solid Tumors 3/23/2017 6:17:25 AM
Ex-Merrimack (MACK) Director Hires Prominent Boston Lawyer to Fight Insider Trading Charges 3/22/2017 7:05:58 AM
Merrimack (MACK) Reports Fourth Quarter And Full-Year 2016 Financial Results 3/1/2017 10:08:14 AM
Merrimack (MACK) Announces Timing Of Fourth Quarter 2016 Investor Conference Call 2/23/2017 11:34:42 AM